BibTeX
@MISC{Bomback_updateson,
author = {Andrew S. Bomback},
title = {Updates on the Treatment of Lupus Nephritis},
year = {}
}
Share
 |
 |
 |
 |
||
OpenURL
Abstract
Renal involvement in systemic lupus er-ythematosus (SLE) continues to be ama-jor contributor tomorbidity andmortal-ity. Up to 50 % of SLE patients will have clinically evident kidney disease at pre-sentation; during follow-up, renal in-volvement will occur in60 % of patients, with an even greater representation among children and young adults.1,2 Lupus ne-phritis impact clinical outcomes in SLE both directly by target organ damage and indirectly through complications of therapy. Recent clinical studies of SLE patients with renal disease, including a number of randomized controlled treat-ment trials, have clarified the therapeutic role of a variety of immunosuppressive regimens both in proliferative andmem-branous lupus nephritis.3 The goal of each of these trials has been to achieve clinical efficacy with a remission of the nephritis while minimizing deleterious side effects of treatment. Although lupus nephritis may affect all compartments of the kidney, glomer-ular involvement is the best-studied component and correlates well with the presentation, course, and treatment of the disease.4 The 2004 modifications in the current International Society of Ne-phrology (ISN)/Renal Pathology Society classification refine and clarify some of the deficiencies of the older World Health Organization (WHO) classifica-tion of lupus nephritis.5 The current ap-proach to treating lupus nephritis—and studying new therapeutic modalities— has largely been guided by histologic findings by ISN class with appropriate consideration of presenting clinical pa-rameters and degree of renal impair-ment.
Keyphrases
lupus nephritis sle patient young adult renal impair-ment appropriate consideration new therapeutic modality renal involvement ama-jor contributor tomorbidity andmortal-ity treat-ment trial clinical pa-rameters clinical efficacy systemic lupus er-ythematosus current ap-proach deleterious side effect best-studied component target organ damage histologic finding world health organization immunosuppressive regimen evident kidney disease recent clinical study current international society therapeutic role isn class renal disease proliferative andmem-branous lupus nephritis glomer-ular involvement renal in-volvement lupus ne-phritis impact clinical outcome renal pathology society classification refine
